Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI

CompletedOBSERVATIONAL
Enrollment

296

Participants

Timeline

Start Date

June 2, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Carcinoma, Non-Small-Cell Lung
Trial Locations (28)

Unknown

Research Site, Aichi

Research Site, Chiba

Research Site, Fukuoka

Research Site, Fukushima

Research Site, Gifu

Research Site, Gunma

Research Site, Hiroshima

Research Site, Hokkaido

Research Site, Hyōgo

Research Site, Ibaraki

Research Site, Ishikawa

Research Site, Kagawa

Research Site, Kanagawa

Research Site, Kyoto

Research Site, Mie

Research Site, Miyagi

Research Site, Miyazaki

Research Site, Nara

Research Site, Okayama

Research Site, Osaka

Research Site, Shizuoka

Research Site, Tochigi

Research Site, Tokyo

Research Site, Tottori

Research Site, Toyama

Research Site, Wakayama

Research Site, Yamagata

Research Site, Yamaguchi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY

NCT05826366 - Imfinzi/Imjudo NSCLC Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - CEI/SCEI | Biotech Hunter | Biotech Hunter